摘要
目的 了解恶性肿瘤患者血清可溶性尿激酶受体 (suPAR)、胸腺肽α1(Tα1)水平和血管性血友病因子裂解酶 (vWF cp)活性水平与患者预后的关系并作比较。方法 以免疫放射分析、酶联免疫吸附试验和残余胶原结合力 (R CBA)的方法分别检测 60例手术前恶性肿瘤患者血清su PAR、Tα1水平和vWF cp活性并随访了 5 1例患者的预后情况。应用Kaplan Meier生存分析了解上述三个指标对恶性肿瘤患者的预后价值并比较之。其临界点选择健康对照数值的均数加 2倍标准差。结果 上述三个指标在术前恶性肿瘤患者中均显著改变 ,但仅suPAR水平和vWF cp活性水平与患者的预后相关。进一步以多元回归分析三个指标对患者预后的影响发现 ,以suPAR的影响最为显著。结论 suPAR可作为恶性肿瘤患者预后判断的可靠指标。
Objective To investigate and compare the prognostic impact of serum solube urokinase receptor (suPAR),thymosin alpha 1 (Tα 1) levels and von Willebrand factor-cleaving protease (vWF-cp) activity in cancer patients.Methods The serum suPAR,Tα 1 levels and vWF-cp activities in 60 cancer patients were measured by immunoradiometric assay,enzyme-linked immunoadsordent assay and residual collagen binding activity(R-CBA),respectively.The prongostic significance of the three molecules in 51 cancer patients was analyzed using Kaplan-Meier survival analysis and Cox’s proportional hazards analysis.Results Although the suPAR,Tα 1 levels and vWF-cp activities significantly altered in cancer patients,only the suPAR level and vWF-cp activities were shown to be related with prognosis.Moreover,Cox’s analysis data showed that the suPAR level was still prongostic significance in multivariate analysis.Conclusion Serum suPAR level is a valuable index in prediction of the prognosis of preoperative cancer patients.
出处
《临床内科杂志》
CAS
2005年第1期22-24,共3页
Journal of Clinical Internal Medicine
关键词
尿激酶受体
胸腺素Α1
血管性血友病因子
裂解酶
肿瘤
预后
Urokinase receptor
Thymosin alpha 1
von Willebrand factor, cleaving protease
Neoplasms
Prognosis
